US Adalimumab Outlook Brightens At Mid-Point Of 2024

PBMs Face Increasing Pressure Over Suppressing Uptake For Humira Biosimilars

 
• By David Wallace
Chart showing trending up in 2024
Uptake is beginning to ramp up for US adalimumab biosimilars in 2024 • Source: Shutterstock

More from Market Intelligence

More from In Vivo